Updated Amplification Tool Rapidly Detects Mycoplasma

Why It Matters

Accelerating Mycoplasma detection enables biopharma manufacturers to release cell‑based products faster, reducing waste and meeting stringent regulatory timelines.

Key Takeaways

• New NAAT cuts Mycoplasma testing from 28 days to hours
• Assay detects 183 Mollicutes species with single‑copy sensitivity
• No cross‑reactivity with 14 non‑Mycoplasma genera validated
• Works on standard qPCR platforms, no special equipment needed
• Higher reagent cost per sample; best for initial screening

Pulse Analysis

Mycoplasma contamination remains a critical quality concern for biologics, especially cell‑based therapies where a 28‑day culture can delay product release and increase the risk of batch expiry. Pharmacopoeias in the U.S., EU and Japan now endorse nucleic acid amplification techniques (NAAT) as a faster alternative, yet existing multiplex assays often sacrifice either breadth of species coverage or analytical sensitivity. The new assay from the National Institute for Food and Drug Control and partners addresses this trade‑off by integrating three primer‑probe sets that collectively span 183 Mollicutes species, delivering single‑copy detection limits comparable to the most sensitive strain‑specific tests.

Technically, the method leverages short 100‑200 bp amplicons and achieves 95‑105% amplification efficiency, ensuring robust quantitation across diverse sample matrices. Validation against 10 pharmacopoeia standard strains and 14 non‑Mycoplasma genera confirms both high sensitivity and specificity, while repeatability tests demonstrate consistent performance. Crucially, the workflow fits seamlessly onto existing qPCR platforms, eliminating the need for costly instrumentation upgrades. The primary trade‑off is a modest increase in per‑sample reagent expense due to the three‑set multiplex design, positioning the assay as an optimal front‑line screening tool followed by confirmatory digital PCR if needed.

For the biopharmaceutical industry, the ability to confirm Mycoplasma‑free status within hours translates into same‑day batch release for cell therapies and faster market entry for recombinant proteins with limited shelf life. This speed advantage can reduce inventory holding costs, mitigate product loss from expiration, and enhance compliance with Chinese and European regulatory expectations. As manufacturers seek to streamline bioprocessing pipelines, adoption of this assay could become a differentiator, especially for firms scaling up personalized cell‑based treatments where time‑to‑patient is paramount. Future work expanding the assay’s robustness against rare or environmental Mycoplasma strains will further cement its role in modern biomanufacturing.